Agile Stock Analysis


USD 0.28  0.02  6.67%   

The big decline in price over the last few months for Agile Therapeutics could raise concerns from investors as the firm is trading at a share price of 0.28 on 1,229,100 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Agile Therapeutics or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.55. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Agile Therapeutics partners.
Please continue to Trending Equities.
The Agile Therapeutics stock analysis report makes it easy to digest most publicly released information about Agile Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Agile Stock analysis module also helps to analyze the Agile Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Agile Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agile Therapeutics recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. The firm had 40.00 - 1.00 split on the 27th of April 2022. Agile Therapeutics, Inc., a womens healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. Agile Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 30 people. For more info on Agile Therapeutics please contact Alfred Altomari at 609 683 1880 or go to

Agile Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Agile Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Agile Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Agile Therapeutics generated a negative expected return over the last 90 days
Agile Therapeutics has high historical volatility and very poor performance
Agile Therapeutics has some characteristics of a very speculative penny stock
Agile Therapeutics has a very high chance of going through financial distress in the upcoming years
The company currently holds 13.19 M in liabilities with Debt to Equity (D/E) ratio of 4.81, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Agile Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Agile Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Agile Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Agile Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Agile to invest in growth at high rates of return. When we think about Agile Therapeutics' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 5.75 M. Net Loss for the year was (69.53 M) with loss before overhead, payroll, taxes, and interest of (6.62 M).
Agile Therapeutics currently holds about 3.74 M in cash with (65.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 25.0% of Agile Therapeutics shares are held by company insiders
Latest headline from Check Out Agile Therapeutics Inc. s Trade Data Rather Than the Analysts Views - SETE News

Agile Therapeutics Upcoming and Recent Events

Earnings reports are used by Agile Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Agile Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Agile Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Agile Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Agile Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Agile Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
24th of August 2022
Financial Statements and Exhibits. Other Events
19th of August 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
25th of July 2022
Entry into a Material Definitive Agreement
13th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure
12th of July 2022
Unclassified Corporate Event
11th of July 2022
Unclassified Corporate Event
8th of July 2022
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement

Agile Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Agile Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agile Therapeutics backward and forwards among themselves. Agile Therapeutics' institutional investor refers to the entity that pools money to purchase Agile Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Perceptive Advisors LlcCommon Shares532.4 K620 K
Renaissance Technologies LlcCommon Shares122.5 K143 K
Jane Street Group LlcCommon Shares92.3 K108 K
Investor AbCommon Shares87.8 K103 K
Citigroup IncCommon Shares58.6 K68 K
Blackrock IncCommon Shares47.6 K56 K
Two Sigma Investments LpCommon Shares45.4 K53 K
Note, although Agile Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Agile Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 34.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Agile Therapeutics's market, we take the total number of its shares issued and multiply it by Agile Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (99.06) % which means that it has lost $99.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (367.94) %, meaning that it created substantial loss on money invested by shareholders. Agile Therapeutics management efficiency ratios could be used to measure how well agile therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 28th of September, Agile Therapeutics shows the mean deviation of 6.98, and Risk Adjusted Performance of (0.09). Agile Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Agile Therapeutics, which can be compared to its rivals. Please confirm Agile Therapeutics semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Agile Therapeutics is priced correctly, providing market reflects its regular price of 0.28 per share. As Agile Therapeutics appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Agile Therapeutics Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Agile Therapeutics's momentum and the point in time when Agile Therapeutics has higher than normal probability directional change.

Agile Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Agile Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Agile Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Agile Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Agile Therapeutics Predictive Daily Indicators

Agile Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Agile Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Agile Therapeutics Forecast Models

Agile Therapeutics time-series forecasting models is one of many Agile Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Agile Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Agile Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Agile Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Agile shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Agile Therapeutics. By using and applying Agile Stock analysis, traders can create a robust methodology for identifying Agile entry and exit points for their positions.
Agile Therapeutics, Inc., a womens healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey. Agile Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.

Current Agile Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Agile analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Agile analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Agile Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Agile analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Agile stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Agile Therapeutics, talking to its executives and customers, or listening to Agile conference calls.
Agile Analyst Advice Details

Agile Stock Analysis Indicators

Agile Therapeutics stock analysis indicators help investors evaluate how Agile Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Agile Therapeutics shares will generate the highest return on investment. By understating and applying Agile Therapeutics stock analysis, traders can identify Agile Therapeutics position entry and exit signals to maximize returns.
Quick Ratio0.39
Fifty Two Week Low0.2620
Revenue Growth1,418.10%
Shares Short Prior Month481.59k
Average Daily Volume Last 10 Day1.78M
Average Daily Volume In Three Month11.62M
Shares Percent Shares Out2.45%
Gross Margins-92.90%
Short Percent Of Float2.45%
Forward Price Earnings-0.34
Float Shares4.17M
Fifty Two Week High41.2000
Enterprise Value To Ebitda-0.19
Fifty Day Average0.4813
Two Hundred Day Average6.9191
Enterprise Value To Revenue2.20
Please continue to Trending Equities. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for analysis

When running Agile Therapeutics price analysis, check to measure Agile Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agile Therapeutics is operating at the current time. Most of Agile Therapeutics' value examination focuses on studying past and present price action to predict the probability of Agile Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Agile Therapeutics' price. Additionally, you may evaluate how the addition of Agile Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Agile Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agile Therapeutics. If investors know Agile will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agile Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Agile Therapeutics is measured differently than its book value, which is the value of Agile that is recorded on the company's balance sheet. Investors also form their own opinion of Agile Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Agile Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agile Therapeutics' market value can be influenced by many factors that don't directly affect Agile Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agile Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Agile Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agile Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.